[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
Explore this paper's citation graph
Summary
The identification of the EML4-ALK rearrangement in 5% of NSCLC enhanced the development of 1st generation ALK inhibitors such as crizotinib, and new drugs such as ceritinib, alectinib and AP26113 are presented.
- Type
- review
- Published
- 2015-04-01
- Cited by
- 9
- References
- 40
- OpenAlex
- https://openalex.org/W322108277
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:196213931
Keywords
Crizotinib, Alectinib, Ceritinib, Medicine, KRAS
References
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
- Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
- Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer
- EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
- Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
- Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
- Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
- Treating ALK positive lung cancer: Early successes and coming challenges
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
- Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Cited by
- Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling.
- An update of ALK inhibitors in human clinical trials.
- ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics
- Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients.
- Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
- Mise en place d’entretiens thérapeutiques par visioconférence pour des patients traités par thérapie ciblée per os dans le cancer bronchique non à petites cellules
- 早期非小细胞肺癌ALK阳性患者的临床研究进展
- Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules , hors immunothérapie News about targeted therapies in non-small-cell lung cancer in 2015 ( except immunotherapy )
Related papers
- Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
- Stepping in the right direction but still some ways to go
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation
- Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
- Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
- Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
- Exploring the optimal use of alectinib.
- Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK‐Rearranged Non–Small‐Cell Lung Cancer: A Retrospective Analysis